MicroRNA signature obtained from the comparison of aggressive with indolent non-hodgkin lymphomas: Potential prognostic value in mantle-cell lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2903-2911

  Goswami, Rashmi S ^a,b   Atenafu, Eshetu G ^c   Xuan, Yali ^a   Waldron, Levi ^j   Reis, Patricia P ^a,k   Sun, Thomas ^d   Datti, Alessandro ^d,l   Xu, Wei ^c   Kuruvilla, John ^c   Good, David J ^e   Lai, Raymond ^h   Church, Alanna J ^g   Lam, Wilson S ^g   Baetz, Tara ^g   Le Brun, David P ^g   Sehn, Laurie H ⁱ   Farinha, Pedro ⁱ   Jurisica, Igor ^b,c   Bailey, Denis J ^f   Gascoyne, Randy D ⁱ   Crump, Michael ^c   Kamel Reid, Suzanne ^a,b,f   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^l UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MICRORNA; PARAFFIN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANADA; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE SEVERITY; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LYMPHOCYTIC LYMPHOMA; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

FEMALE; GENE EXPRESSION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MICRORNAS; MIDDLE AGED; PARAFFIN EMBEDDING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891467425     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.3050     Document Type: Article

References (77)

1. Smedby KE, Hjalgrim H: Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 21:293-298, 2011
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
3. Higgins RA, Blankenship JE, Kinney MC: Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 132:441-461, 2008
4. Kumar V, Abbas AK, Fausto N, et al: Robbins & Cotran: Pathologic Basis of Disease (ed 9). Philadelphia, PA, Elsevier, 2010
5. Zhou Y, Wang H, Fang W, et al: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113:791-798, 2008
6. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003
7. Herrmann A, Hoster E, Zwingers T, et al: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511-518, 2009
8. Bosch F, Ló pez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
9. Majlis A, Pugh WC, Rodriguez MA, et al: Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 15:1664-1671, 1997
10. Nagy B, Lundán T, Larramendy ML, et al: Abnormal expression of apoptosis-related genes in haematological malignancies: Overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120:434-441, 2003
11. Orchard J Garand R Davis Z et al: A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101: 4975-4981 2003
12. Salaverria I, Zettl A, Beà S, et al: Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25:1216-1222, 2007
13. Schrader C, Meusers P, Brittinger G, et al: Topoisomerase II alpha expression in mantle cell lymphoma: A marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 18:1200-1206, 2004
14. Walsh SH, Thorsé lius M, Johnson A, et al: Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 101:4047-4054, 2003
15. Wiestner A, Tehrani M, Chiorazzi M, et al: Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109:4599-4606, 2007
16. Yatabe Y, Nakamura S, Seto M, et al: Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol 20:1110-1122, 1996
17. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advancedstage mantle cell lymphoma. Blood 111:558-565, 2008
18. Iorio MV, Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 27:5848-5856, 2009
19. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297, 2004
20. Di Leva G, Calin GA, Croce CM: MicroRNAs: Fundamental facts and involvement in human diseases. Birth Defects Res C Embryo Today 78:180-189, 2006
21. Harfe BD: MicroRNAs in vertebrate development. Curr Opin Genet Dev 15:410-415, 2005
22. Garzon R, Calin GA, Croce CM: MicroRNAs in cancer. Annu Rev Med 60:167-179, 2009
23. Bloomston M, Frankel WL, Petrocca F, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297:1901-1908, 2007
24. Calin GA, Ferracin M, Cimmino A, et al: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801, 2005
25. Cummins JM, Velculescu VE: Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:6220-6227, 2006
26. Garzon R, Volinia S, Liu CG, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183-3189, 2008
27. Marcucci G, Radmacher MD, Maharry K, et al: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1919- 1928, 2008
28. Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436, 2008
29. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756, 2004
30. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198, 2006
31. Di Lisio L, Gó mez-López G, Sánchez-Beato M, et al: Mantle cell lymphoma: Transcriptional regulation by microRNAs. Leukemia 24:1335-1342, 2010
32. Zhao JJ, Lin J, Lwin T, et al: MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115: 2630-2639, 2010
33. Doleshal M, Magotra AA, Choudhury B, et al: Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 10:203-211, 2008
34. Goswami RS, Waldron L, Machado J, et al: Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol 10:47, 2010
35. Determann O Hoster E Ott G et al: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111: 2385-2387, 2008
36. R Development Core Team, R: A language and environment for statistical computing, v2.8.1. Vienna, Austria, 2008
37. Rinaldi A, Poretti G, Kwee I, et al: Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma 48:410-412, 2007
38. Navarro A, Beà S, Fernández V, et al: MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas. Cancer Res 69: 7071-7078, 2009
39. Ota A, Tagawa H, Karnan S, et al: Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64:3087-3095, 2004
40. Xiao C Srinivasan L Calado DP et al: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414, 2008
41. He L, Thomson JM, Hemann MT, et al: A microRNA polycistron as a potential human oncogene. Nature 435:828-833, 2005
42. Kawamata N, Ogawa S, Gueller S, et al: Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array. Exp Hematol 37:937-946, 2009
43. Rao E, Jiang C, Ji M, et al: The miRNA-17-92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 26:1064-1072, 2012
44. Jiang P, Rao EY, Meng N, et al: MicroRNA- 17-92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol 5:100, 2010
45. Chen RW, Bemis LT, Amato CM, et al: Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 112:822-829, 2008
46. Deshpande A, Pastore A, Deshpande AJ, et al: 3-UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle 8:3584-3592, 2009
47. Iqbal J, Shen Y, Liu Y, et al: Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 119: 4939-4948, 2012
48. Leich E, Zamo A, Horn H, et al: MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood 118:5550-5558, 2011
49. Ng SB, Yan J, Huang G, et al: Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 118:4919-4929, 2011
50. Sander S, Bullinger L, Klapproth K, et al: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112:4202-4212, 2008
51. Sander S, Bullinger L, Wirth T: Repressing the repressor: A new mode of MYC action in lymphomagenesis. Cell Cycle 8:556-559, 2009
52. Fabbri M, Croce CM, Calin GA: MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma 50:160-170, 2009
53. Fabbri M, Garzon R, Andreeff M, et al: MicroRNAs and noncoding RNAs in hematological malignancies: Molecular, clinical and therapeutic implications. Leukemia 22:1095-1105, 2008
54. Herling M, Patel KA, Khalili J, et al: TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20:280-285, 2006
55. Pekarsky Y, Santanam U, Cimmino A, et al: Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66: 11590-11593, 2006
56. Chan TO, Rittenhouse SE, Tsichlis PN: AKT/ PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositidedependent phosphorylation. Annu Rev Biochem 68: 965-1014, 1999
57. Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999-3004, 2004
58. Schneider B, Nagel S, Kaufmann M, et al: T(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29. Leukemia 22:1262-1766, 2008
59. Narducci MG, Arcelli D, Picchio MC, et al: MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2:e151, 2011
60. Wang W, Corrigan-Cummins M, Hudson J, et al: MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 97:586-594, 2012
61. Alencar AJ, Malumbres R Kozloski GA, et al: MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 17:4125-4135, 2011
62. Fischer L, Hummel M, Korfel A, et al: Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13:1090-1098, 2011
63. Robertus JL, Harms G, Blokzijl T, et al: Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol 22:547-555, 2009
64. Imig J, Motsch N, Zhu JY, et al: MicroRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 39:1880-1893, 2011
65. Di Lisio L, Martinez N, Montes-Moreno S, et al: The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 120:1782-1790, 2012
66. Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102:3627-3632, 2005
67. Kluiver J, Poppema S, de Jong D, et al: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207:243-249, 2005
68. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:13520-13525, 2008
69. Santanam U, Zanesi N, Efanov A, et al: Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 107:12210-12215, 2010
70. Visone R, Veronese A, Rassenti LZ, et al: MiR- 181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118:3072-3079, 2011
71. Arribas AJ, Campos-Martín Y, Gó mez-Abad C, et al: Nodal marginal zone lymphoma: Gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood 119:e9-e21, 2012
72. Bouteloup M, Verney A, Rachinel N, et al: MicroRNA expression profile in splenic marginal zone lymphoma. Br J Haematol 156:279-281, 2012
73. Leucci E, Onnis A, Cocco M, et al: B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer 126:1316-1326, 2010
74. Desai S, Maurin M, Smith MA, et al: PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res 8:907-918, 2010
75. Jiang, A, Zhang S, Li Z, et al: MiR-615-3p promotes the phagocytic capacity of splenic macrophages by targeting ligand-dependent nuclear receptor corepressor in cirrhosis-related portal hypertension. Exp Biol Med (Maywood) 236:672-680, 2011
76. Eucker J, Sterz J, Krebbel H, et al: Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anticancer Drugs 17:763-769, 2006
77. Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209-1213, 2008